English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Pro

Presents the zaia usage as premium feature

ZAIA

Presents AI Discovery search usage as a premium feature

AI Discovery

Presents AI Discovery explain and summary usage as a premium feature

Content Analysis

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Presents the pdf analysis as premium feature

PDF Analysis

1500 Top-up

3000 Top-up

Zendy Basic

2500 Top-up

Zendy Unlimited

Presents the access of premium content as premium feature

Premium Content

In December 2019, a novel virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of pneumonia in China. As known, this infection then resulted in a pandemia, being still some territories accross the World suffering from that. Currently, there is no specific treatment or approved vaccine and many clinical trials are investigating potential drugs. Among them, immunomodulators seems a group of drugs that could be useful in the Coronavirus-19 disease (Covid-19). Specially, in those cases where a cytokine storm occurs. This involves a considerable release of proinflammatory cytokine including several interleukins and tumour necrosis factor α (TNF-α) . Here, we report the successful treatment of a metastatic colorectal cancer patient hospitalized due to SARS-CoV-2 pneumonia with tocilizumab, an humanized monoclonal antibody against the interleukin-6 receptor (IL-6R).

archives of clinical and medical case reports

Tocilizumab As A Potential Treatment for SARS-CoV2 Pneumonia in Cancer Patients: A Case Report of A Patient with Clinical-Radiological Dissociated Response